Assessment of patient engagement and adherence with once-daily IND/GLY/MF Breezhaler digital companion in asthma: interim analysis from Germany

Clinical Research Results Abstract IntroductionInadequate adherence to inhaled asthma therapy is associated with poor clinical outcomes. Digital companion paired inhaler devices may improve treatment adherence. Once-daily indacaterol/glycopyrronium/mometasone (IND/GLY/MF) Breezhaler®, approved in EU for inadequately controlled asthma, included the first digital companion (sensor and smartphone application [app]) that can be prescribed alongside treatment. This interim analysis from Germany assessed treatment adherence and engagement with IND/GLY/MF Breezhaler® digital companion in patients with asthma.MethodsPatients (aged ≥18 years) prescribed Breezhaler® digital companion for ≥30 days were included. Assessments by age group: mean % medication adherence (number of puffs taken/prescribed×100 [days 15–30 and 76–90]); mean % app engagement (opening and viewing ≥1 app feature over the first 30 days).ResultsOf 135 enrolled patients (mean age: 47 years), 117 had ≥1 month adherence data. Mean baseline adherence was 82% (68–90% across age groups). Mean baseline app engagement was 72% (68–75% across age groups). At 3-month follow-up (n=42), mean daily adherence was 82% (Table).ConclusionsPatients using Breezhaler® digital companion showed good medication adherence (82%) and app engagement. Long-term data from this program may help understand factors associated with improved medication adherence and app engagement in these patients. Research Idea Abstract Service Development & Evaluation Abstract Declaration of Interest Holger Woehrle: Receives grant/research support from Novartis, ResMed; honoraria or consultation fees from Astra Zeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, ResMed, Sanofi; Head of the working group on Digitization of the German Board of Pulmonologists, Co-Chair of the sleep medicine group of the German Respiratory Society​.Funding: The study was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States. References and Clinical Trial Registry Information